NASDAQ:MRSN Mersana Therapeutics (MRSN) Stock Price, News & Analysis $0.62 +0.00 (+0.68%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Mersana Therapeutics Stock (NASDAQ:MRSN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mersana Therapeutics alerts:Sign Up Key Stats Today's Range$0.58▼$0.6350-Day Range$0.61▼$2.6852-Week Range$0.56▼$6.28Volume7.70 million shsAverage Volume1.55 million shsMarket Capitalization$76.42 millionP/E RatioN/ADividend YieldN/APrice Target$5.57Consensus RatingModerate Buy Company OverviewMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Read More… Mersana Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks84th Percentile Overall ScoreMRSN MarketRank™: Mersana Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 179th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingMersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMersana Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Mersana Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mersana Therapeutics are expected to grow in the coming year, from ($0.61) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mersana Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.16% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Mersana Therapeutics has recently decreased by 0.67%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-0.69 Percentage of Shares Shorted7.16% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Mersana Therapeutics has recently decreased by 0.67%, indicating that investor sentiment is improving. News and Social Media1.5 / 5News Sentiment-0.32 News SentimentMersana Therapeutics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Mersana Therapeutics this week, compared to 3 articles on an average week.Search Interest15 people have searched for MRSN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,512.00 in company stock.Percentage Held by Insiders11.80% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mersana Therapeutics' insider trading history. Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Stock News HeadlinesMersana Therapeutics CEO sells $2,618 in stockJanuary 18 at 8:26 PM | msn.comMersana Therapeutics chief development officer sells shares worth $3,444January 18 at 10:32 AM | msn.comGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. January 20, 2025 | Crypto 101 Media (Ad)Mersana Therapeutics' chief accounting officer sells shares worth $2,061January 17 at 11:48 PM | msn.comMersana Therapeutics officer Timothy Lowinger sells $4,667 in stockJanuary 17 at 11:48 PM | msn.comMersana Therapeutics' chief legal officer sells $599 in stockJanuary 16, 2025 | msn.comMersana therapeutics VP Mandelia sells $1,128 in stockJanuary 16, 2025 | msn.comMersana Therapeutics (NASDAQ:MRSN) Given Outperform Rating at WedbushJanuary 13, 2025 | americanbankingnews.comSee More Headlines MRSN Stock Analysis - Frequently Asked Questions How have MRSN shares performed this year? Mersana Therapeutics' stock was trading at $1.43 at the beginning of the year. Since then, MRSN stock has decreased by 56.7% and is now trading at $0.6186. View the best growth stocks for 2025 here. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics's revenue for the quarter was up 63.6% on a year-over-year basis. When did Mersana Therapeutics IPO? Mersana Therapeutics (MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' top institutional investors include SG Americas Securities LLC (0.09%) and Avanza Fonder AB (0.05%). Insiders that own company stock include Andrew A F Hack, Timothy B Lowinger, Anna Protopapas, Martin H Jr Huber, Brian Deschuytner, Alejandra Carvajal, Ashish Mandelia, Mohan Bala, Arvin Yang and Tushar Misra. View institutional ownership trends. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Saia (SAIA), Rambus (RMBS), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings11/13/2024Today1/20/2025Next Earnings (Estimated)2/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$5.57 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+800.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-171,670,000.00 Net Margins-214.20% Pretax Margin-212.99% Return on Equity-401.37% Return on Assets-38.61% Debt Debt-to-Equity Ratio13.35 Current Ratio2.35 Quick Ratio2.35 Sales & Book Value Annual Sales$36.85 million Price / Sales2.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book2.00Miscellaneous Outstanding Shares123,530,000Free Float108,956,000Market Cap$76.42 million OptionableOptionable Beta1.43 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:MRSN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.